Evaluating a targeted Palbociclib-Trastuzumab loaded smart niosome platform for treating HER2 positive breast cancer cells

Evaluating a targeted Palbociclib-Trastuzumab loaded smart niosome platform for treating HER2 positive breast cancer cells

In this study, we present a targeted and pH-sensitive niosomal (pHSN) formulation, incorporating quantum dot (QD)-labeled Trastuzumab (Trz) molecules for the specific delivery of Palbociclib (Pal) to cells overexpressing human epidermal growth factor receptor 2 (HER2). FTIR analyses confirmed the su...

Full description

Bibliographic Details
Main Authors: Shaghayegh Saharkhiz, Negar Nasri, Nazanin Naderi, Ghasem Dini, Saeid Shirzadi Ghalehshahi, Fateme Firoozbakht
Format: Article
Language:English
Published: Elsevier 2024-06-01
Series:International Journal of Pharmaceutics: X
Subjects:
Drug delivery
Trastuzumab
Monoclonal antibody
pH-sensitive
Niosome
Online Access:http://www.sciencedirect.com/science/article/pii/S2590156724000094

Internet

http://www.sciencedirect.com/science/article/pii/S2590156724000094

Similar Items